Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Inflammatory events in endometrial adenocarcinoma Wallace AE; Gibson DA; Saunders PT; Jabbour HNJ Endocrinol 2010[Aug]; 206 (2): 141-57Endometrial adenocarcinoma is the most common gynaecological malignancy in western countries. Many of the established risk factors for developing endometrial cancer are associated with excess exposure to oestrogen unopposed by progesterone. These include nulliparity, late onset of the menopause, post-menopausal hormone replacement therapy and obesity. However, a number of risk factors also promote inflammation, another feature proposed to influence cancer development. The human cycling endometrium undergoes regular and cyclical episodes of inflammation. Moreover, hormonal and genetic changes that occur early in the development of endometrial adenocarcinoma can exacerbate the local inflammatory environment. Via alterations in the expression of local mediators and immune cell function, these may contribute to the development of endometrial cancer. This review discusses the contribution of inflammation to the initiation and progression of endometrial adenocarcinoma. Manipulation of inflammatory pathways may therefore represent a therapeutic target in endometrial adenocarcinoma.|*Inflammation/genetics/immunology/metabolism[MESH]|Adenocarcinoma/metabolism/*pathology/physiopathology[MESH]|Androgens/metabolism[MESH]|Chemokines/immunology[MESH]|Cytokines/immunology[MESH]|Disease Progression[MESH]|Endometrial Neoplasms/metabolism/*pathology/physiopathology[MESH]|Estrogens/metabolism[MESH]|Female[MESH]|Gene Expression Regulation, Neoplastic[MESH]|Glucocorticoids/metabolism[MESH]|Humans[MESH]|Leukocytes/immunology[MESH]|Menstruation/immunology[MESH]|Mutation[MESH]|NF-kappa B/metabolism[MESH]|PTEN Phosphohydrolase/genetics[MESH]|Progesterone/metabolism[MESH]|Prostaglandins/metabolism[MESH]|Proto-Oncogene Proteins p21(ras)[MESH]|Proto-Oncogene Proteins/genetics[MESH]|Risk Factors[MESH]|Signal Transduction[MESH]|Transcription, Genetic[MESH]|Up-Regulation[MESH]|ras Proteins/genetics[MESH] |